Viking Therapeutics jumps 24% after Phase 1 obesity data, Longeveron falls 64% on mid-stage setback

In September biotech stocks showed wide swings, with Viking Therapeutics gaining 24% and Longeveron dropping 64% as investors reacted to clinical data and trial setbacks.

Viking reported Phase 1 results for its injectable GLP-1/GIP dual agonist VK2735, showing 17.7% weight loss at 21 weeks and a tolerable safety profile, positioning the drug as a potential maintenance therapy for obesity.

The positive readout helped Viking secure a major capital raise and lifted its share price, while analysts highlighted the advantage of weekly dosing.

Longeveron saw a sharp decline after a mid-stage trial setback, prompting questions about its pipeline progress and financing outlook.

The broader biotech index fell modestly for the month, underscoring the sector’s sensitivity to individual trial outcomes.